<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555603</url>
  </required_header>
  <id_info>
    <org_study_id>A4061096</org_study_id>
    <nct_id>NCT04555603</nct_id>
  </id_info>
  <brief_title>Axitinib Therapy Management Study</brief_title>
  <official_title>Retrospective Analysis of Axitinib Treatment Optimization and Management of Selected Immune Related Adverse Events of Checkpoints Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study is to describe axitinib therapy management through use of the&#xD;
      data to be generated by ConcertAI&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To describe type of immune related adverse events and adverse events related to axitinib</measure>
    <time_frame>during treatment period</time_frame>
    <description>describe type of immune related adverse events and adverse events related to axitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To describe the percentage of patients with documentation of dose modifications</measure>
    <time_frame>during treatment period</time_frame>
    <description>describe dose modifications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To describe the percentage of patients with usage of concomitant high-dose corticosteroid</measure>
    <time_frame>during treatment period</time_frame>
    <description>descriptive assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To describe the percentage of patients alive at pre-specified time points (6 months, 12 months, 18 months, 24 months) from start of the index therapy</measure>
    <time_frame>during study period</time_frame>
    <description>calculation of overall survival time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate the best overall response (partial response, complete response, progressive disease, or stable disease</measure>
    <time_frame>during treatment period</time_frame>
    <description>description of overall response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate time to treatment discontinuation</measure>
    <time_frame>during treatment period</time_frame>
    <description>calculation of duration of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate PFS</measure>
    <time_frame>during treatment period</time_frame>
    <description>calculation of progression free survival</description>
  </primary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inlyta</intervention_name>
    <description>axitinib</description>
    <other_name>Axitinib as prescribed in the real world</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bavencio</intervention_name>
    <description>avelumab</description>
    <other_name>Avelumab as prescribed in the real world</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keytruda</intervention_name>
    <description>Pembrolizumab</description>
    <other_name>Pembrolizumab as prescribed in the real world</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        academic and community centers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of aRCC (Stage III, Stage IV (M0) or Stage IV (M1)) at any point&#xD;
&#xD;
               -  Age 18 years or older at the time of aRCC diagnosis&#xD;
&#xD;
               -  Received a qualifying IO-containing combination (nivolumab and ipilimumab,&#xD;
                  axitinib and pembrolizumab, or axitinib and avelumab) in the first regimen after&#xD;
                  aRCC diagnosis or axitinib monotherapy in any line&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A4061096</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Avelumab</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

